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 BRIEF COMMUNICATIONS 
for lymph node – negative invasive breast 
cancer in premenopausal (Trial VIII) and 
postmenopausal (Trial IX) women. Trial 
VIII ( 14 ) evaluated whether sequential 
treatment with six 28-day courses of com-
bination chemotherapy with cyclophos-
phamide, methotrexate, and 5-ﬂ uorouracil 
(CMF) followed by 18 monthly subcuta-
neous implants of goserelin (CMF → 
goserelin) improved disease-free survival 
compared with either six 28-day courses of 
CMF alone or 24 monthly implants of 
goserelin alone. Trial IX ( 15 ) evaluated 
whether sequential treatment with three 
28-day courses of CMF followed by tamox-
ifen for 57 months (CMF → tamoxifen) 
improved disease-free survival compared 
with tamoxifen alone for 60 months. During 
 The percentage of proliferating cells in a 
tumor (ie, the tumor proliferation fraction) 
is an established predictor of breast cancer 
prognosis (1,2). The proliferation antigen 
Ki-67 is detectable in cells at all phases of 
the cell cycle except G 0 ( 3 ), and the Ki-67 
labeling index (the percentage of cells with 
Ki-67 – positive nuclear immunostaining) is 
a measure of tumor proliferation ( 4 , 5 ) that 
has been associated with breast cancer out-
come in several studies (6 – 10). Other stud-
ies ( 11 , 12 ) have suggested that a high Ki-67 
labeling index is predictive of responsive-
ness to neoadjuvant (primary) chemother-
apy, but, to our knowledge, there are no 
such reports concerning Ki-67 labeling 
index as a predictor of responsiveness to 
adjuvant chemotherapy. 
 In 2005, the ninth St Gallen consensus 
conference on primary therapy for early 
breast cancer ( 13 ) emphasized the impor-
tance of the endocrine responsiveness of 
the tumor in selecting adjuvant therapy for 
early breast cancer and acknowledged the 
existence of a group of patients whose 
responsiveness to endocrine therapy is 
uncertain even though their tumors express 
hormone receptors. Because these patients 
may beneﬁ t from chemoendocrine therapy, 
we examined whether the Ki-67 labeling 
index could identify patients who might 
particularly beneﬁ t from the addition of 
chemotherapy to endocrine therapy in the 
adjuvant setting in two International Breast 
Cancer Study Group (IBCSG) trials. 
 IBCSG Trials VIII ( 14 ) and IX ( 15 ) 
were randomized clinical trials that were 
conducted between 1988 and 1999; the 
median follow-up for each trial is 10 
years. The trials compared adjuvant endo-
crine therapy alone with sequential che-
motherapy followed by endocrine therapy 
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 Several small studies have reported that having a high percentage of breast tumor 
cells that express the proliferation antigen Ki-67 (ie, a high Ki-67 labeling index) 
predicts better response to neoadjuvant chemotherapy. However, the predictive 
value of a high Ki-67 labeling index for response to adjuvant chemotherapy is 
unclear. To investigate whether Ki-67 labeling index predicts response to adjuvant 
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apy alone for node-negative breast cancer. A high Ki-67 labeling index was associ-
ated with other factors that predict poor prognosis. Among the 1521 patients with 
endocrine-responsive tumors, a high Ki-67 labeling index was associated with 
worse disease-free survival but the Ki-67 labeling index did not predict the relative 
efficacy of chemoendocrine therapy compared with endocrine therapy alone. Thus, 
Ki-67 labeling index was an independent prognostic factor but was not predictive of 
better response to adjuvant chemotherapy in these studies. 
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the conduct of these trials, the estrogen 
receptor (ER) and the progesterone recep-
tor (PgR) status of the tumor and tumor 
size and grade were locally assessed and 
noted on trial case report forms. Tumors 
were graded 1 – 3 either according to Bloom 
and Richardson ( 16 ) or according to overall 
differentiation as well differentiated (grade 
1), moderately differentiated (grade 2), or 
poorly differentiated (grade 3). 
 In 2003, the IBCSG completed the 
retrospective collection of formalin-ﬁ xed, 
parafﬁ n-embedded primary breast tumor 
tissue samples that were obtained from 
Trials VIII and IX participants. The collec-
tion program was conducted in accordance 
with institutional guidelines and national 
laws. The samples were subjected to immu-
nohistochemical assessment of ER, PgR, 
and HER2 expression and Ki-67 labeling 
index at the IBCSG Central Laboratory 
in Milan, Italy, by personnel who were 
blinded to participant treatment assign-
ment and outcomes, as previously described 
( 17 ). Whole tumor sections were incubated 
with the speciﬁ c primary mouse monoclo-
nal antibodies to ER (clone 1D5, 1  :  100 
dilution) or PgR (clone 1A6, 1  :  800 dilu-
tion) (both from Dako, Glostrup, Denmark). 
HER2 immunoreactivity was assessed using 
a HercepTest kit (Dako) as recommended 
by the manufacturer and scored for the 
intensity of immunostaining, the complete-
ness of cell membrane staining, and the 
percentage of immunoreactive neoplastic 
cells by using a four-tier scale from 0 to 3+, 
as previously described ( 18 ). The centrally 
assessed values of ER, PgR, and HER2 
status were used in this report. 
 Reassessment of the trial conclusion 
based on the centrally assessed hormone 
receptor values conﬁ rmed the ﬁ nding that 
the beneﬁ t of chemotherapy was limited 
to patients whose breast tumors expressed 
little or no ER or PgR ( 17 , 19 ). 
 Tumor material was available and 
assessable for Ki-67 labeling index for 758 
(71%) of 1063 Trial VIII patients and 1166 
(70%) of 1669 Trial IX patients. Ki-67 
labeling index was assessed using mouse 
monoclonal antibody MIB-1 (1  :  200 dilu-
tion; Dako); the percentage of cells that 
showed deﬁ nite nuclear immunoreactivity 
with MIB-1 among 2000 invasive neoplas-
tic cells in randomly selected high-power 
(×400) ﬁ elds at the periphery of the tumor 
was recorded. 
 Centrally reviewed ER and PgR status 
were classiﬁ ed as present ( ≥ 1% immunoreac-
tive cells) or absent (<1% immunoreactive 
cells). Samples were considered to be positive 
for HER2 overexpression if the staining 
intensity score was 3+ and negative for HER2 
overexpression if the staining intensity score 
was 0, 1+, or 2+ ( 20 ). The Ki-67 labeling 
index was dichotomized to high ( ≥ 19% 
immunoreactive cells) and low (<19% immu-
noreactive cells) groups by using the median 
value of Ki-67 immunoreactivity as the cut 
point, which was based on the frequency dis-
tributions of the Ki-67 labeling index in the 
two trial cohorts ( Fig. 1, A and B ). 
 Univariate and multivariable logistic 
regression modeling was used to assess the 
association of other tumor features with 
high vs low Ki-67 labeling index. Analyses 
were undertaken separately for the two 
trials. These analyses revealed that in both 
trials, higher tumor grade, larger tumor 
size, and the absence of tumor expression 
of ER and of PgR were associated with a 
high Ki-67 labeling index ( P < .001 for 
each) (Supplementary Table 1, available 
online). HER2 overexpression was associ-
ated with a high Ki-67 labeling index in 
postmenopausal patients (ie, Trial IX; 
 P < .001) but not in premenopausal patients 
(ie, Trial VIII;  P = .61) (Supplementary 
Table 1, available online). 
 We next examined the association of 
high and low Ki-67 labeling indices with 
disease-free survival among patients with 
endocrine-responsive breast cancer (ie, 923 
patients with ER-present tumors on Trial 
IX and 598 patients with ER- and/or PgR-
present tumors on Trial VIII). Cox pro-
portional hazards modeling was used to 
examine interactions of Ki-67 labeling 
index and other tumor characteristics with 
disease-free survival. To check assumptions 
of proportionality, curves of the log of the 
cumulative hazard function for each value 
of a covariate adjusted for other covariates 
in the model were plotted and assessed 
visually to determine if the vertical shift 
between the curves was constant over time. 
The data appeared to meet the assumptions 
of proportionality. All  P values are two-
sided, and statistical signiﬁ cance was 
deﬁ ned as  P less than or equal to .05. 
 Among postmenopausal patients who 
were treated in Trial IX, a high Ki-67 
labeling index was associated with worse 
disease-free survival (hazard ratio [HR] of 
recurrence or death = 1.60, 95% conﬁ -
dence interval [CI] = 1.26 to 2.03,  P < .001). 
A multivariable analysis adjusting for other 
tumor features conﬁ rmed that high Ki-67 
labeling index was an independent prog-
nostic feature ( P  ≤ .05) (data not shown). 
We examined the pairwise interactions of 
the other tumor features and Ki-67 label-
ing index with disease-free survival to 
investigate whether the association between 
Ki-67 labeling index and disease-free sur-
vival varied as a function of speciﬁ c tumor 
characteristics. There was no evidence of 
an interaction for any factor: a high Ki-67 
labeling index was consistently associated 
with worse disease-free survival ( Fig. 2 ). As 
was previously reported for Trial IX as a 
whole ( 15 ), treatment arm was not associ-
ated with disease-free survival in this endo-
crine-responsive subgroup of patients. 
There was no interaction of Ki-67 labeling 
index and treatment arm with disease-free 
survival ( P interaction = .45;  Fig. 2 ), indicating 
that patients whose tumors had a high Ki-
67 labeling index had worse disease-free 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Some studies have suggested that having a 
high percentage of breast tumor cells that 
label with an antibody against the prolifera-
tion antigen Ki-67 predicts a better response 
to primary (ie, neoadjuvant) chemotherapy. 
 Study design 
 A retrospective assessment of the predic-
tive value of a high Ki-67 labeling index for 
response to therapy among women enrolled 
in two randomized trials of adjuvant che-
moendocrine therapy vs endocrine therapy 
alone for node-negative breast cancer. 
 Contribution 
 A high Ki-67 labeling index did not predict 
which women would benefit from further 
treatment with chemotherapy added to 
endocrine therapy. 
 Limitations 
 Only women with node-negative breast 
cancer were included in this study. 
 Implications 
 Other biomarkers are needed to define 
which women with endocrine-responsive 
node-negative early breast cancer could 
benefit from the addition of adjuvant che-
motherapy to endocrine therapy.  
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survival than patients whose tumors had a 
low Ki-67 labeling index regardless of the 
treatment they received. The relative treat-
ment effect of CMF → tamoxifen vs tamoxi-
fen alone among patients whose tumors 
had a high Ki-67 labeling index (HR = 
1.03, 95% CI = 0.73 to 1.45) was consistent 
with that among patients whose tumors 
had a low Ki-67 labeling index (HR = 0.86, 
95% CI = 0.61 to 1.20). This homogeneity 
in the treatment effect was conﬁ rmed in a 
multivariable analysis that adjusted for 
tumor grade, tumor size, and PgR and 
HER2 status: in patients with ER-express-
ing tumors, a high Ki-67 labeling index did 
not predict resistance to tamoxifen alone; 
nor did it predict beneﬁ t from sequential 
CMF → tamoxifen ( P interaction = .41). 
 Among premenopausal patients who 
were treated in Trial VIII, high Ki-67 
labeling index was associated with worse 
disease-free survival (HR of recurrence 
or death = 1.66, 95% CI = 1.20 to 2.29; 
 P = .002). A multivariable analysis that 
adjusted for other tumor features con-
ﬁ rmed that a high Ki-67 labeling index was 
an independent prognostic marker ( P < .05) 
(data not shown). We examined the pair-
wise interactions of other tumor features 
and Ki-67 labeling index with disease-free 
survival. There was no evidence of an inter-
action for any factor: a high Ki-67 labeling 
index was consistently associated with 
worse disease-free survival ( Fig. 2 ). As was 
previously reported for Trial VIII as a 
whole ( 14 ), treatment arm was not associ-
ated with outcome in this endocrine-
responsive subgroup of patients. There was 
no interaction of Ki-67 labeling index and 
treatment arm with disease-free survival 
( P interaction = .90;  Fig 2 ) , indicating that 
patients whose tumors had a high Ki-67 
labeling index had worse disease-free sur-
vival than patients whose tumors had low 
Ki-67 labeling index regardless of treat-
ment received. The relative treatment 
effect of each pairwise comparison of the 
three treatment arms among patients whose 
tumors had a high Ki-67 labeling index was 
consistent with that among patients with 
low tumor Ki-67 labeling index (CMF →
 goserelin vs goserelin alone in patients with 
low [HR = 0.78, 95% CI = 0.44 to 1.40] and 
high [HR = 0.81, 95% CI = 0.48 to 1.38] 
Ki-67 labeling index; CMF → goserelin vs 
CMF in patients with low [HR = 1.05, 95% 
CI = 0.56 to 1.99] and high [HR = 0.92, 
95% CI = 0.55 to 1.52] Ki-67 labeling index; 
CMF vs goserelin in patients with low 
[HR = 0.74, 95% CI = 0.41 to 1.35] and high 
 Fig. 1 .  Distribution and subpopulation treatment effect pattern plots 
(STEPP) analysis of breast cancer tumor Ki-67 labeling index. 
Frequency distribution of Ki-67 labeling index in postmenopausal 
patients (Trial IX) with estrogen receptor (ER) – expressing tumors ( A ) 
and in premenopausal patients (Trial VIII) with ER- and/or progester-
one receptor (PgR) – expressing tumors ( B ). The  black circles indicate 
the median Ki-67 labeling index, and the  horizontal lines indicate the 
range for subpopulations of patients that were used for the STEPP 
analysis.  C and  D ) STEPP analysis of 5-year disease-free survival by 
treatment arm according to Ki-67 labeling index in postmenopausal 
patients (Trial IX) with ER-expressing tumors ( C ) and in premeno-
pausal patients (Trial VIII) with ER- and/or PgR-expressing tumors ( D ). 
Overlapping subpopulations of patients were deﬁ ned on the basis of 
Ki-67 labeling index, and the resulting patterns of the treatment 
effects estimated within each subpopulation are displayed. The sub-
populations have a ﬁ xed number of patients (approximately 120 for 
Trial IX and approximately 100 for Trial VIII); each subsequent sub-
population changed by 20 patients. The x-axis indicates the median 
Ki-67 labeling index value for patients in each subpopulation; the 
y-axis indicates the treatment effects, expressed as the 5-year disease-
free survival percentage estimated by using the Kaplan-Meier 
method. DFS = disease-free survival; LI = labeling index; CMF = com-
bination chemotherapy with cyclophosphamide, methotrexate, and 
5-ﬂ uorouracil. 
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[HR = 0.89, 95% CI = 0.53 to 1.48] Ki-67 
labeling index). This homogeneity in the 
treatment effects was conﬁ rmed in a multi-
variable analysis that adjusted for tumor 
grade, tumor size, and PgR and HER2 
status: in patients with ER-expressing 
tumors, a high Ki-67 labeling index did not 
predict resistance or beneﬁ t to any of the 
treatments ( P interaction = .69). 
 We further examined the pattern of 
treatment effects across the continuum of 
Ki-67 labeling indices using the nonpara-
metric subpopulation treatment effect pat-
tern plot (STEPP) method ( 21 ), which 
avoids the need to select a cut point in the 
distribution of a continuous feature such as 
Ki-67 labeling index. The STEPP method 
uses a sliding-window approach to deﬁ ne 
several overlapping subpopulations of 
patients according to Ki-67 labeling index 
 and plots the resulting treatment effects 
estimated within each subpopulation. The 
subpopulations have a ﬁ xed number of 
patients (approximately 120 for Trial IX 
and approximately 100 for Trial VIII); each 
subsequent subpopulation changed by 20 
patients. The plot ’ s x-axis indicates the 
median Ki-67 labeling index for patients in 
each subpopulation; the y-axis indicates 
the treatment effects, expressed as the 
5-year disease-free survival percentage 
estimated by using the Kaplan-Meier 
method. We observed no evidence of any 
association between Ki-67 labeling index 
and the relative efﬁ cacy of the trial thera-
pies across the continuum of Ki-67 label-
ing indices ( Fig. 1, C and D ). 
 Our primary goal was to determine 
whether the Ki-67 labeling index of a 
tumor can be used to identify endocrine-
responsive breast cancer patients who 
would beneﬁ t from adjuvant chemother-
apy. Ki-67 has been previously evaluated as 
a prognostic factor (6 – 10), and our ﬁ nding 
that Ki-67 is a prognostic factor in early 
breast cancer is, in general, consistent with 
the conclusions of a recent meta-analysis 
( 22 ) that included more than 12  000 patients 
and our previous study ( 9 ) and those of oth-
ers ( 2 , 6 – 8 , 10 , 23 ) that suggest that higher 
values of Ki-67 indicate a worse prognosis. 
 Several other studies have examined the 
value of using tumor Ki-67 expression to 
predict response to neoadjuvant chemo-
therapy. Chang et al. ( 11 ) and Archer 
et al. ( 12 ) reported an association between 
high pretreatment Ki-67 labeling index 
and better response to chemotherapy in 
the neoadjuvant setting. A 2005 review 
article ( 24 ) cited ﬁ ve small studies (the 
number of patients per study ranged from 
106 to 399) (25 – 29) that investigated the 
predictive value of Ki-67 labeling index in 
 Fig. 2 .  Association between Ki-67 label-
ing index and disease-free survival 
according to other tumor features among 
postmenopausal patients (Trial IX) and 
premenopausal patients (Trial VIII) with 
endocrine-responsive tumors. The  box 
size is inversely proportional to the SE of 
the hazard ratio (HR); the extending  hori-
zontal lines indicate the 95% conﬁ dence 
intervals (CIs); an arrow indicates that 
the conﬁ dence interval extends beyond 
the limits of the x-axis. The  vertical solid 
lines provide a reference for the hazard 
ratio of the overall cohorts, and the 
 dashed line provides a reference for haz-
ard ratio = 1.0. Disease-free survival was 
deﬁ ned as the length of time from the 
date of randomization to any relapse 
(including ipsilateral breast recurrence), 
the appearance of a second primary can-
cer (including contralateral breast can-
cer), or death, whichever occurred ﬁ rst. 
Cox proportional hazards modeling was 
used to estimate hazard ratios and 95% 
conﬁ dence intervals and two-sided 
 P values for pairwise interactions. 
Unknown values are excluded from 
 P value calculations. LI = labeling index; 
CMF = cyclophosphamide, methotrex-
ate, ﬂ uorouracil chemotherapy; PgR = 
progesterone receptor; DFS = disease-
free survival. 
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the neoadjuvant setting; two of these stud-
ies ( 25 , 26 ) concluded that a high Ki-67 
labeling index is associated with response 
to chemotherapy, whereas the other three 
studies ( 27 – 29 ) found no such association. 
 Our data indicate that Ki-67 labeling 
index does not predict which patients will 
beneﬁ t from adding chemotherapy to 
endocrine therapy in the adjuvant setting. 
Instead, our data indicate that a high Ki-67 
labeling index is associated with worse 
disease-free survival in all treatment groups 
and that the association between type of 
treatment and disease-free survival is inde-
pendent of Ki-67 labeling index. Thus, in 
this study, Ki-67 labeling index was a 
prognostic factor, not a predictive factor. 
 A limitation of this study is that it 
included only patients with node-negative 
breast cancer; results may differ in other 
populations. 
 Our results suggest that although tumor 
proliferation fraction as assessed by Ki-67 
labeling index is a valuable prognostic indi-
cator, other biomarkers will be required 
to deﬁ ne which patients with endocrine-
 responsive, node-negative early breast cancer 
would beneﬁ t from the addition of adjuvant 
chemotherapy to endocrine therapy. 
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